Educational reference, not medical advice. This page summarizes information from published research and regulatory filings for educational purposes. It is not a recommendation to use any compound and should not replace guidance from a licensed healthcare provider. Most peptides discussed here are not approved for the uses described.
What it is
Retatrutide + Cagrilintide is a research-peptide combination that pairs two investigational metabolic peptides supplied by some research vendors as a single co-formulated vial. The two components address different hormone axes:
- Retatrutide (LY3437943) is an Eli Lilly–developed triple agonist of the GIP, GLP-1, and glucagon receptors. It produced the largest weight-loss effect ever recorded in a published Phase II trial (mean 24.2% at 48 weeks at the highest dose).
- Cagrilintide (AM833) is a Novo Nordisk–developed long-acting amylin receptor agonist. It is being developed primarily as a fixed-dose combination with semaglutide under the name CagriSema, not with Retatrutide.
It is important to note that the Retatrutide + Cagrilintide pairing is not a registered or even formally evaluated combination. The two components are owned by different companies (Lilly and Novo Nordisk respectively), and no clinical trial has been registered for the pair.
History
- Retatrutide entered clinical development in the early 2020s. The Phase II obesity trial (Jastreboff et al., NEJM 2023) and Phase II diabetes trial established the triple-agonist class. Phase III TRIUMPH program is ongoing.
- Cagrilintide entered clinical development in the late 2010s. The Phase II monotherapy trial (Lau et al., Lancet 2021) established its dose-response for weight management; the Phase Ib combination with semaglutide (Enebo et al., Lancet 2021) led to the CagriSema fixed-dose program, with Phase III REDEFINE 1 and REDEFINE 2 results published in NEJM in 2025.
The Retatrutide + Cagrilintide combination is a research-peptide retail construction, not a pharmaceutical development program. Pre-mixed vials began appearing in research-peptide channels in 2023–2024 alongside the broader interest in next-generation metabolic peptides.
Regulatory status
Neither component has marketing approval anywhere in the world. Both are investigational compounds undergoing Phase III evaluation. The combination as a product is not under regulatory review. The FDA has actively restricted compounding of GLP-1-class peptides as named-drug shortages have been resolved; supplying Retatrutide or Cagrilintide in the United States outside of authorized clinical trials is not consistent with current FDA policy. The combined blend is sold by research-chemical vendors labeled not for human use.
How researchers describe its action
- Retatrutide activates three receptors: GIP (incretin), GLP-1 (incretin), and glucagon (hepatic glucose output and energy expenditure). The glucagon component is hypothesized to contribute additional weight loss through increased basal metabolic rate; the published Phase II trial showed dose-dependent heart-rate elevation consistent with that hypothesis.
- Cagrilintide activates amylin and calcitonin receptors in the brainstem and hypothalamus, promoting satiety and slowing gastric emptying through pathways complementary to GLP-1. Published cryo-EM and pharmacology work characterizes its binding to amylin receptors AMY1 and AMY3.
The rationale for combining the two — that an incretin/glucagon triple agonist could be paired with an amylin analog for additive appetite suppression — is plausible from the component pharmacology but has not been tested in any published study.
Half-life and dosing intervals
Both components are long-acting and engineered for once-weekly subcutaneous administration:
- Retatrutide: approximately 6 days.
- Cagrilintide: approximately 6–7 days.
Both are dose-escalated over several weeks to manage GI side effects. The Phase II obesity trial of Retatrutide tested doses up to 12 mg weekly; Cagrilintide Phase II tested doses up to 4.5 mg weekly. The CagriSema program uses 2.4 mg of each component weekly.
Reconstitution example
Research-peptide vendors typically supply Retatrutide + Cagrilintide as a co-lyophilized vial with supplier-defined ratios. A 30 mg combined vial (15 mg of each) reconstituted with 1.5 mL of bacteriostatic water yields a total peptide concentration of 20 mg/mL — 10 mg/mL of each component. On a 1 mL U-100 insulin syringe, 5 units (0.05 mL) delivers 1 mg of total peptide, split as 0.5 mg of each component.
The dose escalation tested in the component Phase III programs is the basis for cautious starting doses; the combination has no independent dose-titration data.
What to know
- Investigational combination. Neither component is approved, and the two are not being developed together by either Lilly or Novo Nordisk. Retatrutide's combination partner in Lilly's pipeline is not Cagrilintide.
- No human safety data on the combination. Adding a triple agonist and an amylin analog produces compounded GI tolerability burden in principle; this has not been characterized in any controlled study.
- Cardiovascular signal. Retatrutide Phase II reported dose-dependent heart-rate increases that peaked at 24 weeks. Combination effects on cardiovascular parameters have not been evaluated.
- Storage. Refrigerate lyophilized vials. After reconstitution, refrigerate and use within the supplier's stated stability window.
- Reported side effects. Component trial data document nausea, vomiting, and diarrhea as the most common adverse events for both Retatrutide and Cagrilintide, particularly during dose escalation. The combined tolerability profile has not been characterized.
Sources
- 1.Jastreboff AM et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine.
- 2.Lau DCW et al. (2021). Once-weekly cagrilintide for weight management in people with overweight and obesity: a phase 2 trial. The Lancet.
- 3.Enebo LB et al. (2021). Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of cagrilintide with semaglutide 2.4 mg: a phase 1b trial. The Lancet.
- 4.Garvey WT, Blüher M et al. (2025). Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1). NEJM.